Public Citizen Re-Petitions FDA To Withdraw Obesity Drug Meridia
Executive Summary
Public Citizen has renewed its call for FDA to ban Abbott's obesity drug Meridia (sibutramine) following the release of preliminary results of a 10,000 patient study that showed the drug had a slightly higher rate of cardiovascular events
You may also be interested in...
Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia
Abbott is withdrawing its anti-obesity drug sibutramine from the European Union markets at the urging of the European Medicines Agency
Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia
Abbott is withdrawing its anti-obesity drug sibutramine from the European Union markets at the urging of the European Medicines Agency
Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?
The FDA's cardiovascular safety warning on Abbott's obesity drug Meridia (sibutramine) - which was issued in light of early results from a 10,000 patient strong outcomes study - could mean higher regulatory risk for up-and-coming obesity drugs